Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

On Tues 6 June 2017, researchers vaccinated volunteers and began Mahidol University’s study of the malaria vaccine RTS,S/AS01. This is the first study in Asia of the vaccine, an advanced product that has received regulatory approval in Europe.

Nick White and colleagues group photo, and image of vaccine

On Tues 6 June, researchers vaccinated volunteers and began Mahidol University’s study of the malaria vaccine RTS,S/AS01. This is the first study in Asia of the vaccine, an advanced product that has received regulatory approval in Europe.

Several extensive clinical trials of RTS,S/AS01 have previously been conducted in children in sub-Saharan Africa. In a large Phase 3 trial of RTS,S/AS01E at 11 sites in seven sub-Saharan African countries, efficacy against clinical malaria in children aged 5–17 months following three primary doses was 45.1% (CI 41.4 to 48.7), 35.2% (CI 30.5 to 39.5) and 28.3% (CI 23.3 to 32.9) during 20, 32 and 48 months of follow-up, respectively.

Profs. Sasithon (3rd left), Nick White (centre) and colleagues show their delight that Mahidol’s RTS,S/AS01 vaccine study has started. Right: The RTS,S/AS01 vaccine and adjuvant.

While such a “leaky” vaccine is not ideal in high transmission settings, it could be useful in combination with other interventions such as mass drug administrations in the elimination of malaria in the Greater Mekong Subregion, leading malaria researchers say.

“RTS,S is the most advanced of the malaria vaccine candidates. This is the first time the vaccine is evaluated in an Asian population. If found to be safe and effective, RTS,S could be the urgently needed tool to expedite the elimination of malaria in the Greater Mekong Subregion,” said Dr Lorenz von Seidlein, Coordinator of MORU’s TME programme.

Expected to last 6 months, the Mahidol study will recruit 190 health adult volunteers to explore the immunogenicity and safety of various vaccine regimens with and without antimalarial drugs.

Funded by the Malaria Vaccine Initiative/PATH, the study is supervised by Mahidol Prof Sasithon Pukrittayakamee, Dr Borimas Hanboonkunupakarn and Dr Podjanee Jittamala and is coordinated by Pongphaya Pongsuwan. MORU investigators Sir Nick White, Nick Day, Arjen Dondorp and Lorenz von Seidlein will support the study implementation.

Similar stories

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Congratulations Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George

David Warrell, our founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group